Karyopharm Therapeutics
KPTI
115 hedge funds and large institutions have $482M invested in Karyopharm Therapeutics in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 34 reducing their positions, and 17 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 34
0.88% more ownership
Funds ownership: 4.77% → 5.65% (+0.88%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 119 → 115 (-4)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
35% less capital invested
Capital invested by funds: $738M → $482M (-$256M)
38% less call options, than puts
Call options by funds: $553K | Put options by funds: $894K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$8.57M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$8.17M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$7.95M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.77M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.69M |
| 2 |
Millennium Management
New York
|
-$4.37M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.32M |
| 4 |
DAM
Doheny Asset Management
Los Angeles,
California
|
-$1.89M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.66M |
KPTI Hedge Fund Activity: Q4 2018 in Review
115 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2018, worth a combined $482M — down 35% from $738M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of KPTI and 15 opened new positions — a net loss of 2 holders — while 34 trimmed existing stakes and 49 added.
The largest buyer was Emerald Advisers, adding an estimated $8.57M. The largest seller was Vanguard Group, cutting an estimated $7.69M.
- 115 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2018, down from 119 in Q3 2018.
- Funds reported $482M of Karyopharm Therapeutics stock for Q4 2018, down 35% quarter-over-quarter.
- 15 funds opened new Karyopharm Therapeutics positions in Q4 2018 and 17 closed out, a net change of -2 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2018 was Emerald Advisers, an estimated $8.57M added.
- The largest Karyopharm Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $7.69M sold.
Based on aggregated 13F filings for Q4 2018.